According to a study published in the scientific journal The Lancet, the Pfizer / Biotech vaccine is 47% effective between the first and 14th day after the first dose and 85% between the 15th and 28th day.
LThe first dose of the Kovid-19 vaccine from Pfizer / Bioentech was 85% effective two to four weeks after injection, according to a study published in the scientific journal Lancet by medical staff at the largest hospital in France, Israel.
The Hebrew state launched an extensive vaccination campaign against Kovid-19 on December 19, thanks to an agreement with Pfizer that allowed Israel to quickly obtain millions of doses instead of biomedical data on the effect of the vaccine.
So far, 4.23 million Israelis (47% of the population) have been vaccinated with at least the first dose – of which 2.85 million (32%) have the required second dose – according to the Ministry of Health.
Recent Israeli studies have kept the effectiveness of the vaccine at 95% one week after the second dose, while a new study by Sheba Hospital near Tel Aviv Metropolitan estimates it to be 85% two to four weeks after the first dose.
From the start of the vaccine campaign until January 24, the hospital tested 9,109 health workers: 7,214 received the first dose and the remaining 1,895 did not.
During this interval, 170 people from the total sample were identified as carriers of the disease, 89 of whom were in the group of workers who did not receive the first dose.
But only those employees who show symptoms or have had contact with people infected with the virus were tested.
By comparing the rate of contamination in these two combinations of vaccinated and undesirable and at the time of their diagnosis, the Sheba teams found that this vaccine was 47% effective between the first and fourteenth day. Dosage and between 15% 85% and 28th day.
“From two to four weeks after the (first) vaccination, there is already a high rate, with an 85% reduction in symptomatic cases,” Gili Regev-Yochai, co-author of the study, said during a discussion via the Internet. Journalists.
Ms Regev-Yochai said the “big, big, question” remains whether the Pfizer / biotech vaccine would demonstrate its effectiveness in reducing the number of cases of Kovid-19, which would also reduce the transmission of the virus. And add: “We are working on this (…) and hope the good news will come soon”.